GSK Bolsters Gastrointestinal Cancer Portfolio with $1.15B Acquisition of IDRx
In a strategic move to expand its oncology pipeline, GSK plc (LSE/NYSE: GSK) announced on Tuesday, it has entered into
Read moreIn a strategic move to expand its oncology pipeline, GSK plc (LSE/NYSE: GSK) announced on Tuesday, it has entered into
Read moreGlobal biopharmaceutical leader AstraZeneca has officially opened a new $300 million state-of-the-art cell therapy manufacturing facility in Rockville, Maryland, marking
Read moreA research study has showcased the use of Cellendes’ advanced 3-D Life Hydrogel products in developing an immunocompetent, PDMS-free organ-on-chip
Read moreThe unique OptoDrum device for automated in vivo assessment of visual performance in mice and rats offers unmatched capabilities for
Read moreAccelerating Immunoassay Development With Automated Storage, Filling and Labeling – Case Study An HTI Automation & Mabtech Case Study The
Read moreAt Striatech, advancing the future of ophthalmic research is a central commitment. In partnership with the ARVO Foundation for Eye
Read moreMerck KGaA is moving forward with the acquisition of SpringWorks Therapeutics, confirming a definitive agreement at $47 per share in
Read moreEli Lilly and Company announced groundbreaking Phase 2 results for its investigational siRNA therapy lepodisiran, which reduced lipoprotein(a) [Lp(a)] levels
Read moreLexicon Pharmaceuticals announced an exclusive worldwide licensing agreement with Novo Nordisk for LX9851, a first-in-class oral non-incretin therapy in development for
Read moreNovartis has received its third U.S. Food and Drug Administration (FDA) approval for Fabhalta® (iptacopan), marking a major milestone as
Read more